C
Cyrus Therapeutics
Development of small molecule medicines and antibody-drug conjugates (ADCs) targeting previously undruggable cancer targets
About Cyrus Therapeutics
Cyrus Therapeutics is a clinical-stage biotechnology company specializing in the discovery and development of medicines for chronic and life-threatening diseases, with a particular focus on oncology. The company develops small molecule medicines aimed at "undruggable" cancer targets, a significant area of unmet need in the pharmaceutical industry. Cyrus Therapeutics is also advancing its capabilities in targeted protein degradation and possesses technology for optimizing linkers used in Antibody-Drug Conjugate (ADC) cancer therapies.
The company operates in the biotechnology sector, targeting the global oncology market. Its business model is centered on research and development, with the goal of advancing its drug candidates through clinical trials. As a clinical trial-ready company, Cyrus Therapeutics likely seeks to form strategic partnerships with larger pharmaceutical companies for further development, commercialization, and marketing of its proprietary technologies and drug pipeline. The company
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Jan 2022 | $24M | $97M | Mirae Asset Venture Investment · GC Pharma · Atinum Investment · Kolon Investment | ↗ |
| SERIES A✓Equity / VC | Sep 2020 | $8.4M | $34M | Kolon Investment · Timefolio Asset Management · Paratus Investment | ↗ |
Growth signals
Latest recorded traffic for Cyrus Therapeutics is 4.1K monthly website visits, up 86.4% over the last three months. Cyrus Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Cyrus Therapeutics in the Seoul ecosystem
The Cyrus Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
Kolon Investment- TMTimefolio Asset Management
Paratus Investment
Mirae Asset Venture Investment- GPGC Pharma
Atinum Investment
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Cyrus Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Cyrus Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










